Bibliographical noteFunding Information:
Mark A. Frye, M.D., reports grant support from Pfizer , National Alliance for Schizophrenia and Depression (NARSAD), National Institute of Mental Health , National Institute of Alcohol Abuse and Alcoholism , and the Mayo Clinic ; has served as consultant with Merck and Sunovian; and reports Continuing Medical Education-supported activity from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Otsuka Pharmaceuticals, Pfizer, and Sanofi-Aventis. Kendall Lee reports patents pending concerning deep brain stimulation technology and has received industry support from St. Jude Neuromodulation Division. Shirlene Sampson, M.D., received funding from the National Institute of Mental Health. Amit Chopra, Susannah J. Tye, Joseph Matsumoto, Bryan Klassen, Andrea C. Adams, Matt Stead, and Bruce A. Kall report no biomedical financial interests or potential conflicts of interest.